Pseudomonas Aeruginosa Treatment Market Research Report - Global Forecast till 2027

Pseudomonas Aeruginosa Treatment Market Research Report: By Medication (Monotherapy, Combination Therapy), Route of Administration (Oral, Intravenous, Nasal) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Global Forecast to 2027

ID: MRFR/HC/6966-HCR | February 2021 | Region: Global | 105 pages

Please note that the assessment period of report has been updated from 2019-2025 to 2020-2027. Cordially fill the sample form for updated data

Market Forecast


Pseudomonas Aeruginosa Treatment Market is expected to cross USD 7.5 Billion by 2025 at a CAGR of 7%.


Market Synopsis


Pseudomonas Aeruginosa is a soil bacterium that causes infection in animals, plants, and humans. These bacteria frequently cause urinary tract infections (UTIs), lung infection, pneumonia, and chronic pain.


The increasing prevalence of bacterial infection and mortality rate increases the demand for antibiotic drugs. In February 2017, the World Health Organization generated a priority pathogens list for research and development (R&D) of new antibiotics, which includes the bacteria- Acinetobacter baumannii, Pseudomonas aeruginosa, Enterococcus faecium, Staphylococcus aureus, Streptococcus pneumonia, and others.


Also, there is a large number of pharmaceutical companies focused on developing and receiving approvals for Pseudomonas Aeruginosa treatment products. For instance, in February 2018, Allergan Plc, one of the leading pharmaceutical company received the US Food and Drug Administration (FDA) approval for AVYCAZ used for the treatment of hospital-acquired bacterial Pneumonia. The strategic collaboration among the companies is also projected to boost market growth.


Market Influencer


Increasing prevalence of bacterial infection across the global drives the Pseudomonas Aeruginosa treatment market.


Market Drivers




  • Increased use of antibiotics for the treatment of Pseudomonas Aeruginosa infection drives market growth.




  • The increasing mortality rate due to hospital-acquired infection caused due to Pseudomonas Aeruginosa bacteria, especially in immunocompromised hosts. It is found that 32 % of healthcare-acquired infections cause urinary infections, gastrointestinal infections, respiratory system infections, bone and joint infections, and other diseases, which increases the demand for Pseudomonas Aeruginosa treatment.




  • The increasing multidrug resistance bacteria increased the demand for research and innovations in the antibacterial field.




  • The serious symptoms caused due to Pseudomonas Aeruginosa increase the demand for Pseudomonas Aeruginosa treatment across the globe.




  • People having a low immune system are highly prone to affected by Pseudomonas Aeruginosa infection.




Market Restraints



  • Extended use of antibiotics leads to harmful effects on the patient

  • Extensive use of medications develops antibiotic resistance property


Segmentation


By Medication




  • Monotherapy: In this therapy, a single drug is used to treat the disease at the initial stage of infection, and it is cost-effective and likely to have fewer adverse effects compared to other treatment options.




  • Combination Therapy: Combination therapy is recommended for the patient who has developed resistance property against monotherapy. During this therapy, the combination of different drugs is used to treat bacterial infection. This segment is likely to dominate the market with largest market share.




By Route of Administration




  • Oral: It is the largest segment by route of administration. In oral administration, the drug or medicines are delivered through the mouth. The oral treatment methods for Pseudomonas Aeruginosa treatment includes antibiotic drugs.




  • Intravenous: These are the injectable drugs intended for the patient whose Pseudomonas Aeruginosa is not controlled by oral treatment. Tobramycin is an antibiotic available in solution form to treat eye infection, and also available in injectable solution.




  • Nasal: In the nasal route of administration the drug is delivered through the nose as prescribed by the physician. It is a small segment compare to oral and injectable drugs.




By Distribution Channel




  • Hospital Pharmacies: Hospitals are the primary points for diagnosis and treatment for individuals. Hospital pharmacies are the medicals stores available in hospitals.




  • Retail Pharmacies: Retail pharmacies are expected to hold the largest market due to the regular purchasing of medicines for longer run.




  • Online Pharmacies: Provides both prescribed and over the counter (OTC) drugs to the doorstep; this is the fast-growing segment, especially in developed nations.




By Region




  • Americas: The Americas is the largest regional market. An increasing number of chronic diseases, urinary infection, eye infection, bone and joint infections, and other diseases due to Pseudomonas Aeruginosa is likely to drive the growth of the market during the assessment period. The Centers for Disease Control (CDC) estimates that in American hospitals alone, hospital-acquired infections caused 1.7 million infections and 99,000 deaths every year thereby driving the market growth in the region.




  • Europe: Europe has a large number of healthcare companies providing diagnostic and treatment products for Pseudomonas Aeruginosa infection to drive this market growth in this region.




  • Asia-Pacific: The fastest-growing regional market for Pseudomonas Aeruginosa treatment, Asia-Pacific, has a huge population suffering from bacterial infection. Additionally, the growing geriatric population and low immune patients are directly prone to get affected by Pseudomonas Aeruginosa infection, and it is likely to drive the growth of the market.




  • Middle East & Africa: The developing healthcare infrastructure and growing treatment options for Pseudomonas Aeruginosa infection boost the market growth in this region.




Key Players



  • Gilead Sciences Inc. (US)

  • Teva Pharmaceutical Industries Ltd (Israel)

  • Novartis AG (Switzerland)

  • Pfizer, Inc. (UK)

  • Lupin Pharmaceuticals, Inc. (US)

  • PARI Medical Holding GmbH (Germany)

  • AstraZeneca (UK)

  • Humanigen Inc (US)

  • Merck & Co., Inc. (US)

  • AmpliPhi Biosciences Corp (US)

  • Bristol-Myers Squibb Co. (US)

  • Allergan Plc (Ireland)

  • Janssen Pharmaceuticals, Inc. (Belgium)

  • Bayer AG (Germany)

  • Aradigm Corp (US)



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2025: USD 7.5 Billion
  • 2027: Significant Value
  •   CAGR   7% (2019-2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Billion)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Medication, Route of Administration, Distribution Channel
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Gilead Sciences Inc. (US), Teva Pharmaceutical Industries Ltd (Israel), Novartis AG (Switzerland), Pfizer, Inc. (UK), Lupin Pharmaceuticals, Inc. (US), PARI Medical Holding GmbH (Germany), AstraZeneca (UK), Humanigen Inc (US), Merck & Co., Inc. (US), AmpliPhi Biosciences Corp (US), Bristol-Myers Squibb Co. (US), Allergan Plc (Ireland), Janssen Pharmaceuticals, Inc. (Belgium), Bayer AG (Germany), Aradigm Corp (US)
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Increased use of antibiotics for the treatment of Pseudomonas Aeruginosa infection drives market growth.
  • The increasing mortality rate due to hospital-acquired infection caused due to Pseudomonas Aeruginosa bacteria, especially in immunocompromised hosts.
  • The increasing multidrug resistance bacteria increased the demand for research and innovations in the antibacterial field.
  • The serious symptoms caused due to Pseudomonas Aeruginosa increase the demand for Pseudomonas Aeruginosa treatment across the globe.
  • People having a low immune system are highly prone to affected by Pseudomonas Aeruginosa infection.


  • Frequently Asked Questions (FAQ) :


    The valuation of the global pseudomonas aeruginosa treatment market is estimated to reach USD 7.5 BN by 2025.

    The global pseudomonas aeruginosa treatment market is projected to grow at approximately 7% CAGR during the forecast period (2019-2025).

    North America holds the largest share in the global pseudomonas aeruginosa treatment market, followed by Europe and the Asia Pacific, respectively.

    Teva Pharmaceutical Industries Ltd (Israel), Gilead Sciences Inc. (US), Novartis AG (Switzerland), Lupin Pharmaceuticals, Inc. (US), Pfizer, Inc. (UK), PARI Medical Holding GmbH (Germany), Humanigen Inc (US), AstraZeneca (UK), Merck & Co., Inc. (US), Bristol-Myers Squibb Co. (US), AmpliPhi Biosciences Corp (US), Allergan Plc (Ireland), Bayer AG (Germany), Janssen Pharmaceuticals, Inc. (Belgium), and Aradigm Corp (US), are some of the major players operating in the pseudomonas aeruginosa treatment market.



    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.